The primary patency of drug-eluting balloon versus conventional balloon angioplasty in hemodialysis patients with arteriovenous fistula stenoses

Çildağ, Mehmet Burak; Köseoğlu, Ömer Faruk Kutsi; Akdam, Hakan; Yeniçerioğlu, Yavuz

doi:10.1007/s11604-016-0577-8

Cited by 22 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…retrospective study [21], a prospective study [22], and a prospective cohort [23]. Second, the number of censored cases during follow-up was not provided in some of the studies.…”

Section: Plos Onementioning

confidence: 99%

Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials

et al. 2020

View full text Add to dashboard Cite

Background Restenosis remains a significant problem in endovascular therapy for hemodialysis vascular access. Drug-coated balloon (DCB) angioplasty decreases restenosis in peripheral and coronary artery diseases. The aim of this systematic review and meta-analysis is to assess the patency outcomes following DCB angioplasty, as compared to conventional balloon (CB) angioplasty for the stenosis of hemodialysis vascular access. Methods A comprehensive search in the MEDLINE, EMBASE, and CENTRAL databases was conducted in order to identify eligible randomized controlled trials evaluating DCB angioplasty for hemodialysis vascular access dysfunction. The primary endpoint was the 6-month target lesion primary patency and the secondary endpoints were 12-month target lesion primary patency and procedure-related complications. Risk ratios (RR) were pooled and relevant subgroups were analyzed separately. Results Eleven randomized controlled trials comprised of 487 patients treated with DCB angioplasty and 489 patients treated with CB angioplasty were included. There were no significant

show abstract

“…retrospective study [21], a prospective study [22], and a prospective cohort [23]. Second, the number of censored cases during follow-up was not provided in some of the studies.…”

Section: Plos Onementioning

confidence: 99%

Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In our study, the 12-month patency in the DBA group was very similar to that reported by Haave et al ( 26 ), whereas the control arm patency was much higher. In contrast, in another two-cohort study with 26 patients in each of the DBA and PTA groups, Çildağ et al ( 22 ) found no significant difference in the 6-month primary patency rate (77% vs. 65%, respectively, p = 0.45), whereas there was a significant difference in the 12-month primary patency rate (65% vs. 35%, respectively, p < 0.05). These results are not similar to our findings except for the 12-month primary patency in the DBA group.…”

Section: Discussionmentioning

confidence: 89%

“…To date, multiple observational and randomized controlled studies have evaluated the use of DCBs for prolonging patency, but caution should be taken when interpreting the results due to clinical heterogeneity resulting from the non-uniform level of intervention ( 8 9 11 12 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 ). In a retrospective study in 2014, Patanè et al ( 9 ) presented a case series of 26 patients who had juxta-anastomotic radiocephalic stenosis treated using DBA.…”

Section: Discussionmentioning

confidence: 99%

Paclitaxel-Coated Balloon versus Plain Balloon Angioplasty for Dysfunctional Autogenous Radiocephalic Arteriovenous Fistulas: A Prospective Randomized Controlled Trial

Kim

Byun

et al. 2020

Korean J Radiol

View full text Add to dashboard Cite

Objective To report the mid-term results of a single-center randomized controlled trial comparing drug-coated balloon angioplasty (DBA) and plain balloon angioplasty (PBA) for the treatment of dysfunctional radiocephalic arteriovenous fistulas (RCAVFs). Materials and Methods In this prospective study, 39 patients (mean age, 62.2 years; 21 males, 18 females) with RCAVFs failing due to juxta-anastomotic stenosis were randomly assigned to undergo either both DBA and PBA (n = 20, DBA group) or PBA alone (n = 19, PBA group) between June 2016 and June 2018. Primary endpoints were technical and clinical success and target lesion primary patency (TLPP); secondary outcomes were target lesion secondary patency (TLSP) and complication rates. Statistical analysis was performed using the Kaplan-Meier product limit estimator. Results Demographic data and baseline clinical characteristics were comparable between the groups. Technical and clinical success rates were 100% in both groups. There was no significant difference between the groups in the mean duration of TLPP (DBA group: 26.7 ± 3.6 months; PBA group: 27.0 ± 3.8 months; p = 0.902) and TLSP (DBA group: 37.3 ± 2.6 months; PBA group: 40.4 ± 1.5 months; p = 0.585). No procedural or post-procedural complications were identified. Conclusion Paclitaxel-coated balloon use did not significantly improve TLPP or TLSP in the treatment of juxta-anastomotic stenosis of dysfunctional RCAVFs.

show abstract

“…Patients dependent on hemodialysis require a reliable conduit that allows high flow vascular access. With superior patency and lower reintervention rates, the autogenous arteriovenous fistula (AVF) is the preferred form of vascular access [1,2]. However, AVF is prone to restenosis [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…Percutaneous transluminal angioplasty (PTA) is increasingly being accepted as the first-line treatment for restoring luminal diameter [1]. However, PTA has variable technical success rates and high rates of restenosis [3,4,8].…”

Section: Introductionmentioning

confidence: 99%

Use of Paclitaxel Eluting Stents in Arteriovenous Fistulas: A Pilot Study

Dinh

Thomas

Cho

et al. 2019

VSI

View full text Add to dashboard Cite

PurposeWe report short-term patency outcomes of a proof of concept study conducted to determine the efficacy of drug-eluting stent (DES) for the treatment of arteriovenous fistula (AVF) stenosis in hemodialysis patients.Materials and MethodsThis is a single-center, retrospective observational study involving 10 patients with AVF dysfunction treated with DESs between January 2017 and December 2017. The primary outcome was AVF patency confirmed by sonographic and clinical assessment at 1 month and 6 to 9 months after treatment.ResultsA total of 12 DESs were deployed in 10 patients with dysfunctional AVF (radiocephalic: 7, brachiocephalic: 3). During the early follow up (mean: 28.6 days), primary access circuit and DES patency was 100%, with an average volume flow rate of 886.4 mL/min. Nine patients were available for short-term follow up (mean: 202.4 days; 1 unrelated death), with a mean volume flow rate of 1,048.9 mL/min. The primary DES patency was 7/9 (77.8%), and 3 patients required angioplasty at other parts of the circuit (primary access circuit patency: 4/9 [44.4%]). The assisted primary access circuit patency was 77.8%. In 2 patients, the ultrasound revealed that the DESs were thrombosed without any antecedent stenosis; they were salvaged with angioplasty. Both patients previously underwent 2 DESs implanted and recently stopped dual antiplatelet therapy. B-mode sonographic assessment at all timepoints showed minimal intimal ingrowth on the stent struts.ConclusionThis study demonstrates acceptable short-term patency for DESs in the treatment of AVF stenosis. Dual antiplatelet therapy is probably mandatory in the short term.

show abstract

The primary patency of drug-eluting balloon versus conventional balloon angioplasty in hemodialysis patients with arteriovenous fistula stenoses

Abstract: Drug-eluting balloon angioplasty proved to be an effective treatment of hemodialysis AVFs stenosis, with a high primary patency rate at 12 months.

Cited by 22 publications

References 18 publications

Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials

Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials

Paclitaxel-Coated Balloon versus Plain Balloon Angioplasty for Dysfunctional Autogenous Radiocephalic Arteriovenous Fistulas: A Prospective Randomized Controlled Trial

Use of Paclitaxel Eluting Stents in Arteriovenous Fistulas: A Pilot Study

Contact Info

Product

Resources

About